CVS Health (CVS) is in the spotlight after Tennessee Senate Bill 2040 advanced, threatening to force the closure of all company pharmacies in the state. CVS also plans to scale back Medicare Advantage and exit Obamacare exchanges.

At a share price of US$79.90, CVS has seen a 7.22% 1 month share price return and a modest 2.94% 3 month share price return. Its 1 year total shareholder return of 27.81% points to stronger longer term momentum as investors weigh the Tennessee bill, product exits and recent technology initiatives.

If this healthcare news has you rethinking your watchlist, it could be a good moment to look at 28 healthcare AI stocks as potential next names to research.

With CVS trading at US$79.90 and sitting at a discount to analyst targets while being flagged as undervalued on some intrinsic measures, you have to ask: is this a genuine mispricing, or is the market already baking in future growth?

Most Popular Narrative: 23.2% Undervalued

According to the most followed narrative on CVS Health, a fair value of $104.01 sits well above the recent $79.90 share price. This frames CVS as materially discounted while investors debate regulation, insurance exposure and restructuring.

CVS Health’s recent stock drop reveals a deeply undervalued healthcare giant with potential upside if its $2 billion restructuring plan succeeds in boosting profitability and stabilizing growth.

Curious what sits behind that fair value gap? The narrative leans heavily on projected earnings recovery, steadier margins and a long runway from integrated care. The exact mix of revenue growth, profitability and future multiples might surprise you.

Result: Fair Value of $104.01 (UNDERVALUED)

However, this undervaluation story still hinges on CVS executing a complex US$2b restructuring, as well as managing higher medical costs and regulatory pressure in key government programs.

Another View: Earnings Multiple Sends a Very Different Signal

Here is where things get tricky. While intrinsic and narrative models point to CVS as undervalued, the plain P/E picture looks much harsher. At 57.5x earnings versus a US Healthcare average of 23.7x, a peer average of 19.5x and a fair ratio of 43.3x, the stock screens as expensive and carries clear valuation risk. So which story do you trust when the numbers disagree this much?

Next Steps

With such a mixed picture on value and risk, it is worth checking the numbers yourself and deciding quickly where you stand. You can weigh both sides in our breakdown of 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If CVS has you thinking harder about risk and reward, do not stop here. Broaden your watchlist with a few focused ideas that match your own priorities.

• Target potential mispricings by scanning a curated list of 49 high quality undervalued stocks that combine quality fundamentals with more modest market expectations.
• Prioritise resilience by reviewing 76 resilient stocks with low risk scores, where companies show steadier characteristics that may appeal if you want fewer surprises.
• Spot early opportunities by checking our screener containing 24 high quality undiscovered gems, a group of lesser known names that still meet solid fundamental checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.